# Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy

> **NCT05678881** · PHASE1 · TERMINATED · sponsor: **Receptor Life Sciences** · enrollment: 2 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** High dose RLS103
- **DRUG:** placebo inhaled powder
- **DRUG:** Low dose RLS103

## Key facts

- **NCT ID:** NCT05678881
- **Lead sponsor:** Receptor Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-25
- **Primary completion:** 2024-02-23
- **Final completion:** 2024-02-23
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2024-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05678881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05678881, "Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05678881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*